Pyxis Diagnostics

Pyxis Diagnostics is developing an AI-powered cancer diagnostics platform for predicting immuno-oncology (IO) drug response. The company's platform can predict IO drug response for many cancer types. It can also suggest alternative treatment routes in cases when the predicted drug response is low, improving the quality of life of oncological patients. Biological data collected from fresh tumor samples (using cell sorting, next-generation genetic sequencing, and proteomics), enables deep characterization of the cancer cell, different immune cells, and stromal cells. This profound analysis allows for the delineation of the cellular suppressive network (CSN) formed within the tumor microenvironment. Machine-learning algorithms can then be used for classification of responders based on differential CSN patterns. Pyxis Diagnostics aims to improve outcomes for patients and increase success rates of immunotherapies both in clinics and during the drug-development process.

Pyxis Diagnostics has raised $1.2M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Israel Innovation Authority, Vincent Tchenguiz, VLX Ventures.

Pyxis Diagnostics was founded in 2019 by Ravit Geva (CMO), Ilan Volovitz (CSO), Reut Yosef (CTO), Aviv De Morgan (Head of Bioinformatics), Avia Zisso (Research & Development Scientist), Bar Nathansohn (Senior Scientist ).

Pyxis Diagnostics operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Artificial Intelligence, Machine Learning, Biologicals. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Pharmaceuticals.

Pyxis Diagnostics is based in Professor Racah St, Jerusalem, Israel, Jerusalem District.